BioNTech's Q1 vaccine sales triple but it still flags full-year decline

BioNTech's first-quarter sales and earnings more than tripled thanks to demand for the COVID-19 vaccine it developed with Pfizer , but the German biotech firm is still forecasting a full-year decline in vaccine sales.

Quarterly revenues more than tripled from a year earlier to 6.37 billion euros ($6.73 billion), as did net income, to 3.70 billion euros, the company said on Monday.